New HPV test soon on the market
Laboratoire OBO, France – 04 February 2022
The ongoing development of a high-risk human papillomavirus (HPV) detection test using real-time PCR with partial genotyping. This kit will allow for the individualised identification of 3 genotypes associated with the highest carcinogenic potential, namely HPV16, HPV18 and HPV45, and 2 groups simultaneously 45, 31, 33, 52, 58 and 35, 39, 51, 56, 59, 66, 68.
Marketing planned for the 3rd quarter of 2022